The literature cluster reveals a maturing CAR-T ecosystem moving in three converging directions: disease expansion beyond B-cell malignancies, refinement of patient stratification within existing indications, and enabling gene-editing technology to engineer next-generation cell products. Historically validated in B-cell malignancies and B-Cell Malignancy (CLL, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia), CAR T-cell therapy is now being extended as proof-of-concept into acute myeloid leukemia and myelofibrosis, leveraging novel antigen targets such as CD123, MPL, and FAP. In myelofibrosis specifically, a dual therapeutic paradigm is emerging that pairs clonal control of malignant myeloproliferative cells with microenvironmental reprogramming—normalizing the fibrotic bone marrow niche via modulation of the TGF-β axis and CXCR4-CXCL12 signaling, and combining CAR-T with JAK inhibitors for synergistic effect, all grounded in an immunopathogenesis-driven rationale.
Within established indications, particularly diffuse large B-cell lymphoma and transformed indolent non-Hodgkin lymphomas (transformed follicular and marginal zone lymphoma), the field is shifting from broad efficacy reporting toward granular, biology-driven outcome prediction. The Italian CAR-T-SIE registry study demonstrates that transformed indolent NHL patients achieve superior response rates relative to de novo DLBCL, while the CAR-HEMATOTOX score stratifies risk and predicts inferior outcomes across both subgroups with comparable safety profiles (CRS, ICANS). Complementing clinical registries, single-cell-derived CD8+ T cell exhaustion atlases—built via PRISMA-guided synthesis—reveal hierarchical functional subclusters, including a progenitor-exhausted (Tpex) subset that predicts favorable prognosis and CAR-T sensitivity, alongside CD58 pathway impairment as a resistance mechanism. Together these tools point toward cell-state-guided precision immunotherapy, where treatment selection and dosing are informed by tumor microenvironment immune phenotypes rather than histology alone.
Underpinning this expansion is a parallel advance in gene-editing infrastructure: Quadruple pegRNA Prime Editing (QuadPE), which enables programmable insertion of large DNA fragments (1.6–26 kb) with ~40% stable integration efficiency in both dividing (human primary T cells, cell lines) and post-mitotic (neuronal) cells—outperforming transposase- and recombinase-mediated systems by 12-fold and 11–61-fold, respectively. This technology directly addresses a bottleneck in gene therapy for monogenic diseases and rare disease correction, and is positioned to accelerate and improve CAR-T cell engineering itself, closing the loop between synthetic biology tool development and clinical cell-therapy manufacturing.
Collectively, this cluster depicts CAR-T immunotherapy transitioning from a single-target, single-disease modality into a multi-axis platform: broadening disease scope (AML, myelofibrosis), sharpening prognostic/predictive biomarkers (CAR-HEMATOTOX, Tpex, exhaustion subclusters), and adopting more powerful genomic engineering tools (QuadPE) to design more precise, durable, and mechanistically tailored cellular therapeutics.